Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Fractures in nonambulatory children that are not consistent with history or for which no history of injury is given are concerning for abuse ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Antimicrobials, vaccines, anti-inflammatories linked to reduced risk for Alzheimer disease and dementia; antipsychotics and diabetes drugs tied to higher risk ...

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

More than 2 million new cases of cancer will be diagnosed in the US this year, and more than 600,000 people will die of cancer, researchers project.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

RELiZORB is a digestive enzyme cartridge designed to hydrolyze fats contained in enteral formulas, mimicking the function of lipase. The Food and Drug Administration (FDA) has expanded the approval of ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...